Is age the limitation of metastatic treatment prostate cancer?

Abstract

The median age of men with prostate cancer is 67,5 years. We have evidence-based information about elderly with metastatic prostate cancer in clinical trials. The age alone in not a contraindication for ARTA therapy (abiraterone acetate + prednisone, enzalutamide) and chemotherapy (docxetaxel,cabazitaxel). The radium-223 is a therapeutic options for bone metastases. The all possible interactions of treatment should be monitored.